Navigation Links
The dietary supplement genistein can undermine breast cancer treatment
Date:9/23/2008

CHAMPAIGN, Ill. Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report.

Genistein, a soy isoflavone that mimics the effects of estrogen in the body, can negate the effectiveness of aromatase inhibitors, which are designed to reduce the levels of estrogens that can promote tumor growth in some types of breast cancer.

The new study, which included researchers from the University of Illinois, Virginia Polytechnic and State University and the National Center for Toxicological Research, appears in the journal Carcinogenesis.

Aromatase inhibitors are a mainstay of breast cancer treatment in post-menopausal women. These drugs work by interfering with the enzyme aromatase, which catalyzes a crucial step in converting precursor molecules to estradiol, the main estrogen in the body.

About two-thirds of all cases of breast cancer diagnosed in the U.S. are estrogen dependent or estrogen sensitive, which means that the tumors grow more rapidly in the presence of estrogen.

Most women diagnosed with breast cancer are post-menopausal, so their ovaries are no longer producing normal levels of estrogen. Other tissues, however, produce a steroid hormone, androstenedione (AD), which with the help of aromatases is converted to testosterone and estrogens. The estrogens produced from AD can stimulate the growth of some types of breast cancer tumors.

The researchers conducted several trials in a mouse model of estrogen-dependent post-menopausal breast cancer. First, they gave the mice AD, which was converted to estrogen and created a high estrogen environment.

This helped the researchers determine the maximum growth rate of the breast cancer tumors.

Next, they added Letrozole, an aromatase inhibitor widely prescribed to post-menopausal women with estrogen-dependent breast cancer. This treatment (Letrozole) effectively blocked the effects of AD and the breast cancer tumors stopped growing.

But when they added genistein (a plant estrogen or "phytoestrogen" present in many dietary supplements) to the mix, the researchers observed a dose-dependent reduction in the effectiveness of the breast cancer drug. Specifically, the tumors began to grow again. They grew fastest at the highest dietary doses of genistein.

"To think that a dietary supplement could actually reverse the effects of a very effective drug is contrary to much of the perceived benefits of soy isoflavones, and unsettling," said William Helferich a professor of food science and human nutrition at Illinois and principal investigator on the study. "You have women who are taking these supplements to ameliorate post-menopausal symptoms and assuming that they are as safe as consuming a calcium pill or a B vitamin."

Many women take genistein supplements to control hot flashes and other symptoms of menopause. The researchers found that the doses commonly available in dietary supplements were potent enough to negate the effectiveness of aromatase inhibitors.

"These compounds have complex biological activities that are not fully understood," Helferich said. "Dietary supplements containing soy-based phytoestrogens provide high enough dosages that it could be a significant issue to breast cancer patients and survivors."

Plant estrogens from soy are not the only ones of concern, Helferich said. In a recent study, he and his colleagues found that certain mixtures of estrogenic botanical components and extracts marketed as supplements to assist "female libido enhancement" and sold without a prescription appeared to spur breast cancer tumor growth at low doses, while having no effect on tumors at high doses.

That study appeared last year in Food and Chemical Toxicology.

"We are just starting to understand the complex effects of the dietary supplements that contain phytoestrogens," Helferich said. "There is an ongoing human experiment in which the outcome is unknown. These findings raise serious concerns about the potential interaction of the estrogenic dietary supplements with current breast cancer therapies."


'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Related biology news :

1. Researchers uncover details about how dietary restriction slows down aging
2. Market testing of dietary supplements and drugs underscores value of USPs public health programs
3. Changing the global dietary environment
4. Dietary calcium could possibly prevent the spread of breast cancer to bone
5. UF scientists reveal how dietary restriction cleans cells
6. L-1 Identity Solutions to Hold Supplemental Second Quarter 2008 Financial Results Q&A Conference Call at 2:00p.m. (ET) Today
7. Researchers identify cancer preventive properties in common vitamin supplement
8. A nutritional supplement could improve the clinical situation of ICU patients
9. People with diabetes may have all natural citrus supplement
10. Wellmune WGP supplementation alleviates
11. Pediatricians alerted to the developmental nature of underage drinking in special journal supplement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The dietary supplement genistein can undermine breast cancer treatment
(Date:2/9/2017)... The biomass boiler market report by Transparency Market Research ... in terms of revenue (US$ Mn) based on the ... boilers has been segmented on the basis of feedstock ... based on feedstock type, has been segmented into woody ... urban residues, and others. On the basis of product ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 ... Driven largely by the confluence of organizations, desires ... distaste for knowledge-based systems (password and challenge questions), ... industrial, and government systems. The market is driven ... a demarcation between consumer and enterprise uses cases, ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Madison, Wisconsin (PRWEB) , ... February 23, 2017 ... ... their Drug Discovery Services portfolio to include an array of biochemical ... clients with reliable data to drive their hit-to-lead and SAR programs, including inhibitor ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, Inc , (GGI) ... Compass Research . GGI's mission is to advance global health and highlight the greater ... in honor of each clinical trial volunteer. The vision of GGI is to serve ...
(Date:2/22/2017)... Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on ... companion animals, will host a live conference call on Tuesday, ... results from the fourth quarter and full year ended December ... access the audio webcast or use the conference ... ...
Breaking Biology Technology: